PONTIAC II
Research type
Research Study
Full title
NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease (Pontiac II); a prospective randomized trial
IRAS ID
213183
Contact name
John G F Cleland
Contact email
Sponsor organisation
Medical University of Vienna
Eudract number
2015-000239-34
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 3 months, 26 days
Research summary
Patients with Type 2 diabetes mellitus (T2DM) have an increased risk of developing heart disease compared to patients without T2DM, however not all have the same risk. NT-proBNP is a marker in the blood which helps identify which patients have a higher risk of going on to develop heart disease and we would like to investigate a treatment for these patients. In a previous, smaller study (Pontiac I), we were able to show that treating higher risk patients with a Renin Angiotensin System (RAS)-antagonist plus a beta-blocker reduced the risk of developing severe heart failure by more than half. Pontiac II aims to study more patients than Pontiac I and will also study patients with a lower risk of developing heart failure. We hope that Pontiac II will show that treatment of these patients with a high dose of RAS-antagonist plus a beta-blocker will reduce the number of unplanned hospitalisations or the risk of developing worsening heart problems and may also provide a cost benefit to the NHS.
REC name
West of Scotland REC 1
REC reference
17/WS/0228
Date of REC Opinion
5 Dec 2017
REC opinion
Further Information Favourable Opinion